参麦注射液联合常规治疗方案治疗急性心肌梗死的Meta分析  

A Meta-analysis on treatment of acute myocardial infarction with Shenmai Injection combining routine therapeutic plan

作　　者：马志远[1] 孙钰[2] 金艳玲[2] 蒋林[2] 王文进[1] 

机构地区：[1]兰州大学第一医院,兰州730000 [2]兰州大学第一临床医学院

出　　处：《中国循证心血管医学杂志》2013年第6期568-572,共5页Chinese Journal of Evidence-Based Cardiovascular Medicine

摘　　要：目的：系统评价参麦注射液联合常规治疗方案治疗急性ST段抬高型心肌梗死（STEMI）的临床疗效和安全性。方法计算机检索Cochrane Library、PubMed、Embase、中国生物医学文献数据库、中国期刊全文数据库、中文科技期刊全文数据库、检索时间从各数据库建库至2013年1月；同时辅助其他检索，纳入参麦注射液联合常规治疗方案治疗STEMI的随机对照实验（RCTs）。两名评价者独立评价纳入研究的质量并提取资料，并用RevMan 5.2软件进行统计分析。结果共纳入16篇RCTs，共1886例患者，Meta分析结果显示：与单纯常规治疗方案相比，参麦注射液联合常规治疗方案可以降低病死率[比值比（OR）=0.46，95%CI：0.33～0.63，P＜0.00001]、减少休克发生率（OR=0.56，95%CI：0.35～0.89， P=0.01）和心力衰竭发生率（OR=0.51，95%CI：0.37~0.71，P＜0.0001）、降低继发于STEMI的心律失常发生率（OR=0.37，95%CI：0.22~0.63，P=0.0003）方面有统计学差异。结论参麦注射液联合常规方案可降低STEMI治疗的病死率，减少休克和心衰发生率，及继发于STEMI的心律失常发生率，值得临床参考。Objective To review the curative effect and safety of Shenmai Injection combining routine therapeutic plan in treatment of ST-segment elevation myocardial infarction （STEMI）.Methods The databases of Cochrane Library, PubMed, Embase, CBM, CNKI, and CSJD were retrieved with computers from establishing time of these databases to Jan. 2013, and at the same time other retrieving methods were applied for collecting randomized controlled trials （RCT） about Shenmai Injection combining routine therapeutic plan in treatment of STEMI. The quality of all RCT was reviewed and data was extracted by two researchers independently. A Meta-analysis was conducted by using RevMan 5.2 software.Results There were totally 16 RCT included involving 1886 cases. The results of Meta-analysis showed as follows： compared with routine therapeutic plan, Shenmai Injection combining routine therapeutic plan reduced mortality （OR=0.46, 95%CI： 0.33-0.63,P〈0.00001） and incidences of shock （OR=0.56, 95%CI： 0.35~0.89,P=0.01） and heart failure （OR=0.51, 95%CI： 0.37~0.71,P〈0.0001）, and there was statistical difference in the decrease of incidence of arrhythmia secondary to STEMI （OR=0.37, 95%CI：0.22~0.63,P=0.0003）.Conclusion Shenmai Injection combining routine therapeutic plan can reduced mortality and incidences of shock, heart failure and arrhythmia secondary to STEMI in the treatment of STEMI.

关 键 词：参麦 参麦注射液 心肌梗死 META分析 

分 类 号：R542.22[医药卫生—心血管疾病]